NCT00935090View on ClinicalTrials.gov

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

RecruitingINTERVENTIONAL
Timeline

Start Date

September 30, 2009

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2028

Conditions
Brain and Central Nervous System TumorsChronic Myeloproliferative DisordersLeukemiaLymphomaLymphoproliferative DisorderMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DEVICE

3'-deoxy-3'-[18F]fluorothymidine

The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.

Trial Locations (1)

48201-1379

RECRUITING

Barbara Ann Karmanos Cancer Institute, Detroit

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Barbara Ann Karmanos Cancer Institute

OTHER